01 September 2010
Progen Licensee Submits Updated Special Protocol Assessment to US FDA for Phase III Clinical Trails of PI-88
30 June 2010
Preliminary Final Report For Year Ended 30 June 2010
02 July 2010
Progen Nasdaq Delisting Update
28 June 2010
Progen Granted Muparfostat (PI-88) Patent in Japan
30 June 2010
Progen Pharmaceuticals Ltd signs Licence and Collaboration Agreement with Medigen Biotech Corp
24 June 2010
Progen Receives Delisting Notification from Nasdaq
31 May 2010
Shareholder Newsletter
28 May 2010
Appendix 6A Notification - Expiry of Options
27 May 2010
Progen Pharmaceuticals Ltd Subsidiary Secures Manufacturing Contract
24 May 2010
Company Secretary Resignation
19 May 2010
Progen Pharmaceuticals Ltd Granted Muparfostat (PI-88) Patent in Europe
30 April 2010
Progen Pharmaceuticals Ltd Signs Muparfostat (PI-88) to Non-Binding Letter of Intent for License and Collaboration with Medigen Biotech Corp.
20 April 2010
Progen Pharmaceuticals Ltd Subsidiary Secures Manufacturing Contract from Hunter Immunology Ltd
08 April 2010
Muparfostat (PI-88) Reverts Back to Pharmasynth, a Wholly-Owned Subsidiary of Progen Pharmaceuticals Ltd.
29 March 2010
Progen Appoints New CEO
16 March 2010
Corporate Presentation Q1 2010
01 March 2010
Progen Appoints Additional Company Secretary
26 February 2010
Appendix 4D - Interim Financial Report